GB202304841D0 - Promoter - Google Patents

Promoter

Info

Publication number
GB202304841D0
GB202304841D0 GBGB2304841.6A GB202304841A GB202304841D0 GB 202304841 D0 GB202304841 D0 GB 202304841D0 GB 202304841 A GB202304841 A GB 202304841A GB 202304841 D0 GB202304841 D0 GB 202304841D0
Authority
GB
United Kingdom
Prior art keywords
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2304841.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purespring Therapeutics Ltd
Original Assignee
Purespring Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purespring Therapeutics Ltd filed Critical Purespring Therapeutics Ltd
Priority to GBGB2304841.6A priority Critical patent/GB202304841D0/en
Publication of GB202304841D0 publication Critical patent/GB202304841D0/en
Priority to PCT/GB2024/050861 priority patent/WO2024201058A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2304841.6A 2023-03-31 2023-03-31 Promoter Pending GB202304841D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2304841.6A GB202304841D0 (en) 2023-03-31 2023-03-31 Promoter
PCT/GB2024/050861 WO2024201058A1 (en) 2023-03-31 2024-03-28 Promoter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2304841.6A GB202304841D0 (en) 2023-03-31 2023-03-31 Promoter

Publications (1)

Publication Number Publication Date
GB202304841D0 true GB202304841D0 (en) 2023-05-17

Family

ID=86316624

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2304841.6A Pending GB202304841D0 (en) 2023-03-31 2023-03-31 Promoter

Country Status (2)

Country Link
GB (1) GB202304841D0 (en)
WO (1) WO2024201058A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (en) 2013-08-14 2015-02-16 Laurantis Pharma Oy Therapeutic use of VEGF-C and CCBE1
GB202003618D0 (en) * 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) * 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
EP4273243A1 (en) * 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression

Also Published As

Publication number Publication date
WO2024201058A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
CA216403S (en) Hoodie
GB202103470D0 (en) Promoter
CA221971S (en) Thermo-hygrometer
EP4149966A4 (en) Dual promoter systems
GB202304841D0 (en) Promoter
GB202109231D0 (en) Promoter
GB202009410D0 (en) Promoter design
GB202309914D0 (en) Promoters
GB2620440B (en) Hyperconducting arrangement
GB2620443B (en) Hyperconducting arrangement
CA224333S (en) Snuffbox
CA224110S (en) Thermo-hygrometer
CA221849S (en) Plant-clip
CA223625S (en) Aerometer
CA217804S (en) Soundbar
CA217438S (en) Footwarmer
CA215379S (en) E-track
CA214906S (en) Multi-cooker
CA215434S (en) Thermo-hygrometer
CA215433S (en) Thermo-hygrometer
GB201903499D0 (en) Minimal promoter
GB202005473D0 (en) Forskolin-inducible promoters
GB202212764D0 (en) Disclosure
GB202210995D0 (en) Disclosure
GB202411882D0 (en) Hyperconducting arrangement